Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

Core Insights - Eli Lilly announced positive topline results from Phase 3 trials ACHIEVE-2 and ACHIEVE-5, demonstrating the efficacy of orforglipron in reducing A1C levels in adults with type 2 diabetes [1][2][5] ACHIEVE-2 and ACHIEVE-5 Trial Results - In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to a 0.8% reduction with dapagliflozin, meeting the primary endpoint [1][3] - In ACHIEVE-5, orforglipron achieved a 2.1% reduction in A1C when combined with insulin glargine, also meeting the primary endpoint [1][3] - All doses of orforglipron (3 mg, 12 mg, 36 mg) showed statistical significance with p<0.001 against comparators in both trials [3] Safety and Tolerability - The safety profile of orforglipron was consistent with previous studies, with common adverse events being mild-to-moderate gastrointestinal issues [4] - No hepatic safety signals were observed during the trials [4] Future Plans - Detailed results from the trials will be presented at a future medical meeting and published in a peer-reviewed journal [5] - Lilly plans to submit orforglipron for regulatory approval for type 2 diabetes in 2026, with an obesity treatment submission expected by the end of 2025 [5][10] About Orforglipron - Orforglipron is an investigational oral GLP-1 receptor agonist that can be taken without food and water restrictions [6][7] - The ACHIEVE clinical trial program has enrolled over 6,000 participants with type 2 diabetes across five global registration trials [10]